Literature DB >> 18172726

Is C-reactive protein a prognostic factor of colorectal cancer?

Yu-Chen Shiu1, Jen-Kou Lin, Chi-Jung Huang, Jeng-Kai Jiang, Ling-Wei Wang, Huei-Chen Huang, Shung-Haur Yang.   

Abstract

PURPOSE: C-reactive protein, a commonly used inflammation marker, has been reported to be a prognostic factor of colorectal cancer. This prospective study was designed to confirm the prognostic value of its preoperative levels and to observe their perioperative change.
METHODS: Between January 2001 and September 2005, preoperative C-reactive protein levels were obtained for 212 consecutive patients (140 males) receiving elective open resection of colorectal cancer. A level higher than 0.5 mg/dl was defined as positive. They were analyzed against clinicopathologic factors. The survival of 158 curative resections was analyzed. Postoperative levels (at months 1, 3, and 6) were collected for analysis of changing trend, from the patients receiving curative surgeries.
RESULTS: Median value of preoperative C-reactive protein was 0.54 mg/dl (48.6 percent positive). Positive rate was significantly correlated with ulcerative type, larger size, higher stage, and positive carcinoembryonic antigen (>5 ng/ml). In both univariate log-rank test and multiple Cox proportional hazards regression, stage (univariate P = 0.011, and multivariate P = 0.016; hazard ratio, 6.23; 95 percent confidence interval, 1.41-27.54), C-reactive protein (0.5 mg/dl; P = 0.005, and P = 0.016; hazard ratio: 6.51; 95 percent confidence interval: 1.41-30.05), and differentiation (P = 0.006, and P = 0.043; hazard ratio, 3.53; 95 percent confidence interval, 1.04-11.98) were significant factors. Analysis of disease-free interval showed C-reactive protein was significant (P = 0.03): as level rose, prognosis worsened. The quiescent inflammation-response group (< or =0.1 mg/dl) had excellent outcomes. Postoperatively, the C-reactive protein levels declined at the third postoperative month.
CONCLUSIONS: Preoperative C-reactive protein is an independent prognostic factor. The levels declined postoperatively, although with a lag. These findings seem to support the response hypothesis regarding C-reactive protein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18172726     DOI: 10.1007/s10350-007-9133-z

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  21 in total

1.  Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer.

Authors:  Aleksandra M Urbanska; Emmanouil D Karagiannis; Gonzalo Guajardo; Robert S Langer; Daniel G Anderson
Journal:  Biomaterials       Date:  2012-04-01       Impact factor: 12.479

2.  Clinical Significance of the Glasgow Prognostic Score for Survival after Colorectal Cancer Surgery.

Authors:  Tunc Eren; Busra Burcu; Ercument Tombalak; Tugrul Ozdemir; Metin Leblebici; Ibrahim Ali Ozemir; Sedat Ziyade; Orhan Alimoglu
Journal:  J Gastrointest Surg       Date:  2016-02-29       Impact factor: 3.452

3.  Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer.

Authors:  Anna E Coghill; Polly A Newcomb; Peter T Campbell; Andrea N Burnett-Hartman; Scott V Adams; Elizabeth M Poole; John D Potter; Cornelia M Ulrich
Journal:  Gut       Date:  2010-11-04       Impact factor: 23.059

4.  Fish oil decreases C-reactive protein/albumin ratio improving nutritional prognosis and plasma fatty acid profile in colorectal cancer patients.

Authors:  Michel Carlos Mocellin; Juliana de Aguiar Pastore e Silva; Carolina de Quadros Camargo; Maria Emília de Souza Fabre; Scheila Gevaerd; Katya Naliwaiko; Yara Maria Franco Moreno; Everson Araújo Nunes; Erasmo Benicio Santos de Moraes Trindade
Journal:  Lipids       Date:  2013-07-26       Impact factor: 1.880

5.  Arginase and C-reactive protein as potential serum-based biomarker of head and neck squamous cell carcinoma patients of north east India.

Authors:  Biswadeep Choudhury; Shilpee Srivastava; Haider H Choudhury; Alokananda Purkayastha; Sumita DuttaGupta; Sankar Kumar Ghosh
Journal:  Tumour Biol       Date:  2014-04-09

6.  Increased number of forkhead box P3+ tumor-infiltrating lymphocytes correlates with high preoperative albumin level and better survival in patients with stage II or III colorectal cancer.

Authors:  Dong-liang Wang; Yan-yan Liu; Yuan-long Gu; Yu Qin; Hong-fei Ji; Li-hua Wu; Ning Qi; Dan Su; Sun-hui Huang; Yan-qiao Zhang
Journal:  Tumour Biol       Date:  2015-02-20

7.  Preoperative elevation of serum C-reactive protein as an independent prognostic indicator for gastric cancer.

Authors:  Tadahiro Nozoe; Tomohiro Iguchi; Eisuke Adachi; Akito Matsukuma; Takahiro Ezaki
Journal:  Surg Today       Date:  2011-03-23       Impact factor: 2.549

8.  C-reactive protein concentration is associated with prognosis in patients suffering from peritoneal carcinomatosis of colorectal origin.

Authors:  Marcel C G van de Poll; Yvonne L B Klaver; Valery E P P Lemmens; Bart J M Leenders; Simon W Nienhuijs; Ignace H J T de Hingh
Journal:  Int J Colorectal Dis       Date:  2011-04-08       Impact factor: 2.571

9.  C-reactive protein levels: a prognostic marker for patients with head and neck cancer?

Authors:  Astrid L Kruse; Heinz T Luebbers; Klaus W Grätz
Journal:  Head Neck Oncol       Date:  2010-08-02

10.  Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication.

Authors:  Michael I Koukourakis; Georgia Kambouromiti; Dimitra Pitsiava; Pelagia Tsousou; Maria Tsiarkatsi; George Kartalis
Journal:  Inflammation       Date:  2009-06       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.